nach oben

Current Hematologic Malignancy Reports

Erschienen in:

24.09.2016 | Myelodysplastic Syndromes (D Steensma, Section Editor)

An Exercise in Extrapolation: Clinical Management of Atypical CML, MDS/MPN-Unclassifiable, and MDS/MPN-RS-T

verfasst von: Chetasi Talati, Eric Padron

Erschienen in: Current Hematologic Malignancy Reports | Ausgabe 6/2016

Einloggen, um Zugang zu erhalten

Abstract

According to the recently published 2016 World Health Organization (WHO) classification of myeloid malignancies, myelodysplastic/myeloproliferative neoplasms (MDS/MPN) include atypical chronic myeloid leukemia (aCML), MDS/MPN-unclassifiable (MDS/MPN-U), chronic myelomonocytic leukemia (CMML), juvenile myelomonocytic leukemia (JMML), and MDS/MPN ring sideroblasts with thrombocytosis (MDS/MPN-RS-T). MDS/MPN-RS-T was previously a provisional category known as refractory anemia with ring sideroblasts with thrombocytosis (RARS-T) which has now attained a distinct designation in the 2016 WHO classification. In this review, we focus on biology and management of aCML, MDS/MPN-U, and MDS/MPN-RS-T. There is considerable overlap between these entities which we attempt to further elucidate in this review. We also discuss recent advances in the field of molecular landscape that further defines and characterizes this heterogeneous group of disorders. The paucity of clinical trials available secondary to unclear pathogenesis and rarity of these diseases makes the management of these entities clinically challenging. This review summarizes some of the current knowledge of the molecular pathogenesis and suggested treatment guidelines based on the available data.

Sochacki AL, Fischer MA, Savona MR. Therapeutic approaches in myelofibrosis and myelodysplastic/myeloproliferative overlap syndromes. Onco Targets Ther. 2016;9:2273–86.PubMedPubMedCentral

Arber DA et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391–405.CrossRefPubMed

Sallman DA, Padron E. Transformation of the clinical management of CMML patients through in-depth molecular characterization. Clin Lymphoma Myeloma Leuk. 2015;15(Suppl):S50–5.CrossRefPubMed

Harada Y, Harada H. Chronic myelomonocytic leukemia (CMML): recent advances in molecular pathogenesis and treatment. Rinsho Ketsueki. 2016;57(2):147–55.PubMed

Adachi S, Nakahata T. Diagnosis and treatment of juvenile myelomonocytic leukemia (JMML). Nihon Rinsho. 2001;59(12):2401–6.PubMed

Koike K, Matsuda K. Molecular mechanism and progress in treatment of juvenile myelomonocytic leukemia (JMML). Rinsho Ketsueki. 2013;54(6):538–44.PubMed

Sakashita K. Juvenile myelomonocytic leukemia (JMML): recent advances in molecular pathogenesis and treatment. Rinsho Ketsueki. 2016;57(2):137–46.PubMed

Zoi K, Cross NC. Molecular pathogenesis of atypical CML, CMML and MDS/MPN-unclassifiable. Int J Hematol. 2015;101(3):229–42.CrossRefPubMed

Bacher U et al. Distribution of cytogenetic abnormalities in myelodysplastic syndromes, Philadelphia negative myeloproliferative neoplasms, and the overlap MDS/MPN category. Ann Hematol. 2009;88(12):1207–13.CrossRefPubMed

10.

Meggendorfer M et al. SETBP1 mutations occur in 9% of MDS/MPN and in 4% of MPN cases and are strongly associated with atypical CML, monosomy 7, isochromosome i(17)(q10), ASXL1 and CBL mutations. Leukemia. 2013;27(9):1852–60.CrossRefPubMed

11.

Bellesso M et al. Atypical chronic myeloid leukemia with t(9;22)(p24,11.2), a BCR-JAK2 fusion gene. Rev Bras Hematol Hemoter. 2013;35(3):218–9.PubMedPubMedCentral

12.

Muta T, Osaki K, Yamano Y. Translocation t(9;22) (p23;q11) in atypical chronic myeloid leukemia (aCML) presenting osteolytic lesions. Int J Hematol. 2002;76(4):344–8.CrossRefPubMed

13.

Xu Y et al. A BCR-JAK2 fusion gene from ins(22;9)(q11;p13p24) in a patient with atypical chronic myeloid leukemia. Leuk Lymphoma. 2013;54(10):2322–4.CrossRefPubMed

14.

Wang SA et al. Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic/myeloproliferative neoplasms. Blood. 2014;123(17):2645–51.CrossRefPubMedPubMedCentral

15.

Gotlib J et al. The new genetics of chronic neutrophilic leukemia and atypical CML: implications for diagnosis and treatment. Blood. 2013;122(10):1707–11.CrossRefPubMedPubMedCentral

16.

Piazza R et al. Recurrent SETBP1 mutations in atypical chronic myeloid leukemia. Nat Genet. 2013;45(1):18–24.CrossRefPubMed

17.

Breccia M et al. Identification of risk factors in atypical chronic myeloid leukemia. Haematologica. 2006;91(11):1566–8.PubMed

18.

Hernandez JM et al. Clinical, hematological and cytogenetic characteristics of atypical chronic myeloid leukemia. Ann Oncol. 2000;11(4):441–4.CrossRefPubMed

19.

Martiat P, Michaux JL, Rodhain J. Philadelphia-negative (Ph-) chronic myeloid leukemia (CML): comparison with Ph + CML and chronic myelomonocytic leukemia. The Groupe Francais de Cytogenetique Hematologique. Blood. 1991;78(1):205–11.PubMed

20.

Kurzrock R et al. BCR rearrangement-negative chronic myelogenous leukemia revisited. J Clin Oncol. 2001;19(11):2915–26.PubMed

21.

Maxson JE et al. Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML. N Engl J Med. 2013;368(19):1781–90.CrossRefPubMedPubMedCentral

22.

Maxson JE et al. The colony-stimulating factor 3 receptor T640N mutation is oncogenic, sensitive to JAK inhibition, and mimics T618I. Clin Cancer Res. 2016;22(3):757–64.CrossRefPubMed

23.

Geyer JT, Orazi A. Myeloproliferative neoplasms (BCR-ABL1 negative) and myelodysplastic/myeloproliferative neoplasms: current diagnostic principles and upcoming updates. Int J Lab Hematol. 2016;38(1):12–9. doi:10.1111/ijlh.12509.

24.

Gambacorti-Passerini CB et al. Recurrent ETNK1 mutations in atypical chronic myeloid leukemia. Blood. 2015;125(3):499–503.CrossRefPubMed

25.

Hoischen A et al. De novo mutations of SETBP1 cause Schinzel-Giedion syndrome. Nat Genet. 2010;42(6):483–5.CrossRefPubMed

26.

Khanna V et al. Durable disease control with MEK inhibition in a patient with NRAS-mutated atypical chronic myeloid leukemia. Cureus. 2015;7(12):e414.PubMedPubMedCentral

27.

Cortes J et al. Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders. Cancer. 2003;97(11):2760–6.CrossRefPubMed

28.

Koldehoff M et al. Outcome of hematopoietic stem cell transplantation in patients with atypical chronic myeloid leukemia. Bone Marrow Transplant. 2004;34(12):1047–50.CrossRefPubMed

29.

DiNardo CD et al. Myelodysplastic/myeloproliferative neoplasms, unclassifiable (MDS/MPN, U): natural history and clinical outcome by treatment strategy. Leukemia. 2014;28(4):958–61.CrossRefPubMedPubMedCentral

30.

Chaudhury A et al. Prognosis and outcomes in MDS-MPN unclassifiable: single institution experience of a rare disorder. Blood. 2015;126(23):1698.

31.

Alchalby H, Kroger N. Allogeneic stem cell transplant vs. Janus kinase inhibition in the treatment of primary myelofibrosis or myelofibrosis after essential thrombocythemia or polycythemia vera. Clin Lymphoma Myeloma Leuk. 2014;14 Suppl:S36–41.CrossRefPubMed

32.

Eghtedar A et al. Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemia. Blood. 2012;119(20):4614–8.CrossRefPubMedPubMedCentral

33.

Cherington C et al. Allogeneic stem cell transplantation for myeloproliferative neoplasm in blast phase. Leuk Res. 2012;36(9):1147–51.CrossRefPubMed

34.

Steensma DP, Tefferi A. JAK2 V617F and ringed sideroblasts: not necessarily RARS-T. Blood. 2008;111(3):1748.CrossRefPubMed

35.

Papaemmanuil E et al. Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. N Engl J Med. 2011;365(15):1384–95.CrossRefPubMedPubMedCentral

36.

Effenberger KA et al. Interchangeable SF3B1 inhibitors interfere with pre-mRNA splicing at multiple stages. RNA. 2016;22(3):350–9.CrossRefPubMed

37.

Broseus J et al. Age, JAK2(V617F) and SF3B1 mutations are the main predicting factors for survival in refractory anaemia with ring sideroblasts and marked thrombocytosis. Leukemia. 2013;27(9):1826–31.CrossRefPubMed

38.

Jeromin S et al. Refractory anemia with ring sideroblasts and marked thrombocytosis cases harbor mutations in SF3B1 or other spliceosome genes accompanied by JAK2V617F and ASXL1 mutations. Haematologica. 2015;100(4):e125–7.CrossRefPubMedPubMedCentral

39.

Broseus J et al. Low rate of calreticulin mutations in refractory anaemia with ring sideroblasts and marked thrombocytosis. Leukemia. 2014;28(6):1374–6.CrossRefPubMed

40.

Klampfl T et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med. 2013;369(25):2379–90.CrossRefPubMed

41.

Broseus J et al. Clinical features and course of refractory anemia with ring sideroblasts associated with marked thrombocytosis. Haematologica. 2012;97(7):1036–41.CrossRefPubMedPubMedCentral

42.

Cazzola M et al. Biologic and clinical significance of somatic mutations of SF3B1 in myeloid and lymphoid neoplasms. Blood. 2013;121(2):260–9.CrossRefPubMedPubMedCentral

43.

Cortelazzo S et al. Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N Engl J Med. 1995;332(17):1132–6.CrossRefPubMed

44.

Huls G et al. Efficacy of single-agent lenalidomide in patients with JAK2 (V617F) mutated refractory anemia with ring sideroblasts and thrombocytosis. Blood. 2010;116(2):180–2.CrossRefPubMed

45.

Ziarkiewicz M et al. Refractory anaemia with ringed sideroblasts associated with marked thrombocytosis (RARS-T) with superimposed 5q-syndrome. Pol J Pathol. 2010;61(2):105–9.PubMed

46.

Taylor G, Culligan D, Vickers MA. Refractory anemia with ring sideroblasts associated with marked thrombocytosis complicated by massive splenomegaly treated with lenalidomide resulting in resolution of splenomegaly but severe and prolonged pancytopenia. Case Rep Hematol. 2013;2013:718480.PubMedPubMedCentral

47.

Savona MR et al. An international consortium proposal of uniform response criteria for myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in adults. Blood. 2015;125(12):1857–65.CrossRefPubMedPubMedCentral

Titel: An Exercise in Extrapolation: Clinical Management of Atypical CML, MDS/MPN-Unclassifiable, and MDS/MPN-RS-T
verfasst von: Chetasi Talati
Eric Padron
Publikationsdatum: 24.09.2016
Verlag: Springer US
Erschienen in: Current Hematologic Malignancy Reports / Ausgabe 6/2016
Print ISSN: 1558-8211
Elektronische ISSN: 1558-822X
DOI: https://doi.org/10.1007/s11899-016-0350-1

Springer Medizin

An Exercise in Extrapolation: Clinical Management of Atypical CML, MDS/MPN-Unclassifiable, and MDS/MPN-RS-T

Abstract

Neu im Fachgebiet Onkologie

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

Viel pflanzliche Nahrung, seltener Prostata-Ca.-Progression

Alter verschlechtert Prognose bei Endometriumkarzinom

Darf man die Behandlung eines Neonazis ablehnen?

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2016

Molecular Testing in Patients with Suspected Myelodysplastic Syndromes

Extranodal NK/T Cell Lymphoma, Nasal Type (ENKTL-NT): An Update on Epidemiology, Clinical Presentation, and Natural History in North American and European Cases

Social Media and Myeloproliferative Neoplasms (MPN): Analysis of Advanced Metrics From the First Year of a New Twitter Community: #MPNSM

Antibody-Based Treatment of Acute Myeloid Leukemia

Palliative and End-of-Life Care in Myelodysplastic Syndromes

Acute Myeloid Leukemia: How Do We Measure Success?

Neu im Fachgebiet Onkologie

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

Viel pflanzliche Nahrung, seltener Prostata-Ca.-Progression

Alter verschlechtert Prognose bei Endometriumkarzinom

Darf man die Behandlung eines Neonazis ablehnen?

Update Onkologie